Osborne Clarke advises on the sale of MILabs to Rigaku Corporation

Osborne Clarke in Amsterdam has advised the shareholders of MILabs on the sale of the company's entire issued share capital to Rigaku Corporation.

Since its foundation in 2006, MILabs has provided leading-edge imaging devices with the development of novel PET, SPECT, CT, and Optical Tomography technologies. The MILabs scanners are mainly used in oncological research, but are also suitable for e.g. heart and brain research. Customers worldwide include universities, pharmaceutical companies and so-called CROs, companies that do research for pharmaceutical companies at a highly specialised level.

Rigaku is a leading manufacturer of X-ray analysis equipment based in Tokyo that has been active for over 70 years.

As part of the Rigaku group, MILabs expects to be able to grow further internationally. Rigaku will strengthen MILabs’ sales capabilities by leveraging Rigaku’s sales network, and by utilizing Rigaku’s global service network, the two companies will be able to deliver even better service to customers. Furthermore, the two companies will also promote joint development of new products by combining MILabs’ technologies in radiation detection and add-on platform system design with Rigaku’s X-ray design technology.

The Osborne Clarke team which advised the shareholders of MILabs, was led by partner Herke van Hulst and Associate Director Marie-Louise Weeda and included junior associate Levi Schutz, Tax partner Job van der Pol and associate Aram Hovanesjan, partner / civil-law notary Cars-Jan van Gool and civil law notaries Arlette Vrolijk and Eveline Leijen, TMC partner Coen Barneveld Binkhuysen and associates Sophie den Held and Gianna Hendriks, associates Marleen Huisman and Romy van Limpt (IP/ data protection) and Employment, Pensions and Incentive partner Jim Margry.

Osborne Clarke’s international life science and healthcare sector team has a strong track record of providing highly sophisticated advice to investors and clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market. Recent notable M&A work from the team in Amsterdam in the life science and healthcare sector includes advising Terumo Corporation on the acquisition of Quirem Medical, ViroClinics Biosciences on the acquisition of DDL Diagnostic Laboratory, assisting on the sale of Isobionics to BASF and the sale of Breath Therapeutics to Zambon.